TMJ Relax

A TMJ therapist in your medicine cabinet

Print
Claim My Business
Security Type
Common Stock
Categories
Service Businesses, Consumer Goods & Products
Min Investment
$499
Location
Medford, MA
Offering Date
April 28, 2022
Expected Close Date
July 21, 2022
Target Raise
$10.00K-$1.07M
No. Investors
21
Security Price
$1.46
Valuation
$8,750,000
Website
tmjrelax.com
Number of Employees
10
Cash
$81,650
Revenue
$43,991
Short Term Debt
$57,234
Cost of Goods
$6,087
Long Term Debt
$57,234
Net Income
$-51,978

Company Description

We believe far too many people suffer from temporomandibular joint disorder, and that an ideal standardized solution does not exist. So we created a solution using computer-aided design and 3D manufacturing. Our goal is to reduce the prevalence of TMJ disorder by making treatment more user-friendly, more effective, and more affordable.

Perks

StartEngine OWNERS Exclusive Click here to learn more

$499+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Early Bird Tier 1
Invest in the first 72 hours, get 25% bonus shares




2
days

12
hours

55
mins

20
secs

Early Bird Tier 2
Invest in the first week, get 20% bonus shares




6
days

12
hours

55
mins

20
secs

Early Bird Tier 3
Invest in the first month, get 15% bonus shares




29
days

12
hours

55
mins

20
secs

$1,500+ Investment
Tier 1 Perk (Invest $1,500+ )
receive 5% bonus shares

$2,500+ Investment
Tier 2 Perk (Invest $2,500+ )
receive 8% bonus shares

$5,000+ Investment
Tier 3 Perk (Invest $5,000+ )
receive 10% bonus shares

$10,000+ Investment
Tier 4 Perk (Invest $10,000+ )
receive 15% bonus shares

$25,000+ Investment
Tier 5 Perk (Invest $25,000+ )
receive 20% bonus shares

Key Deal Facts

We believe far too many people suffer from temporomandibular joint disorder, and that an ideal standardized solution does not exist. So we created a solution using computer-aided design and 3D manufacturing. Our goal is to reduce the prevalence of TMJ disorder by making treatment more user-friendly, more effective, and more affordable.

Management Team / Advisory Board Bios

Maria Dykstra



Lead Digital Marketing Strategist


Maria is the lead digital marketing strategist of TMJ Relax. She serves as the primary consultant for establishing brand awareness via various digital advertising channels including social media marketing, search engine marketing, and email outreach.
Maria is an award-winning social media strategist with roots in creating social success for the global Fortune 100. She understands the strategy behind the social media buzz and has delivered market-growing results across Facebook, Twitter, Instagram, TikTok, LinkedIn and more. 
An accomplished author, speaker and frequent contributor to Huffington Post, Entrepreprenuer.com, Social Media Examiner. Her advice is featured in Forbes, FOX News, Business Insider and other top media.
Maria's engagement with the company is available to scale with the needs of each project. We anticipate her contributions to current projects will average approximately 10-20 hours per week. 















Pam Abrahamsson



Lead Public Relations Strategist


Pam is the lead public relations strategist of TMJ Relax. She serves as the primary consultant regarding company presentation, external marketing collaboration, and earned media strategy.
Pam brings over 16 years experience of industry leadership in program strategy, acquisition communications, crisis management, media outreach, thought leadership development and more. Pam is an experienced entrepreneur and is the Founder and director of PRA Public Relations. Her expertise is award-winning as a leader, author and expert in public communications programs. 
Pam's clients have included Western Union, Finova Financial, Crelate, National Philanthropic Trust, Oracle, Cisco, Market Prophit, Travel Paso Robles Alliance, Shea Properties, Irvine Retail Properties, Promote on Purpose, Global Debt Auto Network and more.
Pam's engagement with the company is available to scale with the needs of each project. We anticipate her contribution to the current projects will average approximately 5-10 hours per week. 















John McDermott



Lead Reimbursement Consultant


John serves as the lead reimbursement consultant, and is engaged to research and develop a novel and effective reimbursement strategy through collaboration with major medical and dental payors. 
John has more than 30 years of experience as a market access, reimbursement, and HEOR consultant and practice leader. John received his A.B. from Dartmouth College with honors in English and a modified major in Native American Studies. He received his M.B.A with a concentration in health services management from the Fuqua School of Business at Duke University.
Through hundreds of engagements for the drug, biotech, and medical device industries, he has evaluated products in a wide variety of therapeutic areas, with deep experience in orthopedics, dentistry, cardiology, urology, oncology, rare diseases, and diagnostic imaging.
John's engagement with the company is available to scale with the needs of each project. We anticipate his contributions to current projects will average approximately 10-20 hours per week. 















Mehdi Kazemzadeh-Narbat



Lead Regulatory Consultant


Dr. Kazemzadeh-Narbat serves as the lead regulatory consultant, and is engaged to research and develop regulatory opportunities to expand the indications of use of TMJ Relax through the de novo pathway, and to provide valuable regulatory guidance on future product offerings. 
Dr. Kazemzadeh-Narbat received his Ph.D. in biomedical engineering from the University of British Columbia, Vancouver in 2012. He also received his MS, and BS in Biomedical engineering from Iran. He has published over 30 peer-reviewed journal articles, with about 1900 citations and h-index 17 (Google Scholar). Mehdi is CQA-certified and actively participates in the regulatory science workshops and conferences.
Dr. Kazemzadeh-Narbat is a former FDA medical device reviewer. During his tenor working US Food and Drug Administration (FDA), Dr. Kazemzadeh-Narbat was working in the Center for Devices and Radiological Health (CDRH), as a pre-market and post-market lead reviewer of Orthopedic (OHT6), and Dental (OHT1) devices. 
Dr. Kazemzadeh-Narbat's engagement with the company is available to scale with the needs of each project. We anticipate his contributions to current projects will average approximately 10-15 hours per week. 















Abigail Allen



Lead Clinical Trials Consultant


Abigail serves as the lead clinical trials strategy consultant, and is engaged to research and develop clinical trial strategy including creation of a protocol synopsis, and the development of the full clinical protocol.
Abigail has more than 15 years’ experience in clinical research. She received her Bachelor of Art in Psychology from American University. Abigail previously worked as a Clinical Manager for a privately held medical device company. She brings value due to her extensive experience assisting small to large clients execute their clinical trials, staying under budget and within anticipated timelines. 
Abigail's engagement with the company is available to scale with the needs of each project. We anticipate her contributions to current projects will average approximately 10-20 hours per week. 















Jonathan Shechter



Corporation Counsel


Attorney Shechter serves as the corporate counsel and advisor regarding general corporation operations and securities.  
Attorney Shechter is a founding partner of Foley Shechter LLP. Previously, he was a corporate and securities attorney with a Wall Street based law firm, as well as the Head of the Corporate Finance group of a New York firm with affiliate offices in Tel Aviv, Israel and Shanghai, China, where he was principally engaged in the practice of corporate and securities law.
Attorney Shechter brings extensive experience in corporate structuring and development including closing corporate finance and M&A transactions. He brings extensive startup legal guidance having worked with a vast array of management teams and boards of directors.
Attorney Shechter engagement with the company is available to scale with the needs of each project. We anticipate his contributions to current projects will average approximately 3-5 hours per week. 















David Boag



Intellectual Property Counsel


Attorney Boag serves as the Intellectual property counsel and advisor. His engagements include strategic consulting and development of utility patents, design patents, trademarks, and trade secrets. 
Attorney Boag is the founder and managing principal of BLPLLC, where he enjoys helping clients with complex and challenging intellectual property issues. A former software developer, he can bridge law and technology, delivering exceptional value to our high-tech clients.
Attorney Boag has a wide range of experience representing clients in federal court and before the U.S. Patent and Trademark Office, including the Patent Trial and Appeal Board and Trademark Trial and Appeal Board.
Attorney Boag's engagement with the company is available to scale with the needs of each project. We anticipate his contributions to current projects will average approximately 10-20 hours per week.
Amount Raised : $107,255
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments